Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-16T07:26:05.563Z Has data issue: false hasContentIssue false
  • English
  • Français

Augmentation of clozapine with ECT: a retrospective case analysis

Published online by Cambridge University Press:  24 September 2020

John Lally Open the ORCID record for John Lally [Opens in a new window] ,
Emily Breese ,
Mugtaba Osman ,
Cai Hua Sim ,
Hitesh Shetty ,
Amir Krivoy  and
James H. MacCabe
John Lally*
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland Department of Psychiatry, Mater Misericordiae University Hospital, Eccles St., Dublin, Ireland Department of Psychiatry, St Vincent’s Hospital Fairview, Dublin, Ireland
Emily Breese
Affiliation:
School of Life, Health and Chemical Sciences, The Open University, Walton Hall, Milton Keynes, UK
Mugtaba Osman
Affiliation:
Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland
Cai Hua Sim
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
Hitesh Shetty
Affiliation:
BRC Case Register, South London and Maudsley NHS Foundation Trust, London, UK
Amir Krivoy
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel
James H. MacCabe
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK National Psychosis Service, South London and Maudsley NHS Foundation Trust, London, UK
*
Author for correspondence: John Lally, Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

We sought to assess the effectiveness of clozapine augmentation with Electroconvulsive therapy (ECT) (C+ECT) in patients with clozapine-resistant schizophrenia.

Methods:

We conducted a retrospective review of electronic health records to identify patients treated with C+ECT. We determined the response to C+ECT and the rate of rehospitalisation over the year following treatment with C+ECT.

Results:

Forty-two patients were treated with C+ECT over a 10-year period. The mean age of the patients at initiation of ECT was 46.3 (SD = 8.2) years (range 27–62 years). The mean number of ECTs given was 10.6 (SD = 5.3) (range 3–25) with the majority receiving twice weekly ECT. Seventy-six per cent of patients (n = 32) showed a Clinical Global Impression-Improvement (CGI-I) score of ≤3 (at least minimally improved) following C+ECT. The mean number of ECT treatments was 10.6 (SD = 5.3) (range 3–25) with the majority receiving twice weekly ECT. Sixty-four per cent of patients experienced no adverse events. Response to C+ECT was not associated with gender, age, duration of illness or duration of clozapine treatment. Seventy-five per cent of responders remained out of hospital over the course of 1-year follow-up, while 70% of those with no response to C+ECT were not admitted to hospital. Three patients received maintenance ECT, one of whom was rehospitalised.

Conclusion:

This study lends support to emerging evidence for the effectiveness of C+ECT in clozapine-resistant schizophrenia. These results are consistent with the results of a meta-analysis and the only randomised controlled trial (RCT) of this intervention. Further RCTs are required before this treatment can be confidently recommended.

Keywords

schizophreniatreatment-resistantelectroconvulsive therapypsychosisclozapine
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 33 , Issue 1 , February 2021 , pp. 31 - 36
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

Both are first named authors and should be acknowledged as such.

References

Agid, O, Arenovich, T, Sajeev, G, Zipursky, RB, Kapur, S, Foussias, G and Remington, G (2011) An algorithm-based approach to first-episode schizophrenia: Response rates over 3 prospective antipsychotic trials with a retrospective data analysis. Journal of Clinical Psychiatry 72(11), 1439–1444.CrossRefGoogle ScholarPubMed
Braga, RJ, John, M, Schooler, NR, Bailine, SH, Malur, C, Mendelowitz, A and Petrides, G (2019) Continuation electroconvulsive therapy for patients with clozapine-resistant schizophrenia: A pilot study. The Journal of ECT 35(3), 156–160.CrossRefGoogle ScholarPubMed
Grover, S, Chakrabarti, S, Hazari, N and Avasthi, A (2017) Effectiveness of electroconvulsive therapy in patients with treatment resistant schizophrenia: A retrospective study. Psychiatry Research 249, 349–353.CrossRefGoogle Scholar
Grover, S, Sahoo, S, Rabha, A and Koirala, R (2019) ECT in schizophrenia: A review of the evidence. Acta Neuropsychiatr 31(3), 115–127.CrossRefGoogle Scholar
Guy, W (1976) ECDEU Assessment Manual for Psychopharmacology, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.Google Scholar
Kho, KH, Blansjaar, BA, De Vries, S, Babuskova, D, Zwinderman, AH and Linszen, DH (2004) Electroconvulsive therapy for the treatment of clozapinenonresponders suffering from schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 254(6), 372–379.CrossRefGoogle ScholarPubMed
Kim, HS, Kim, SH, Lee, NY, Youn, T, Lee, JH, Chung, S, Kim, YS and Chung, IW (2017) Effectiveness of electroconvulsive therapy augmentation on clozapine-resistant schizophrenia. Psychiatry Investigation 14(1), 58–62.CrossRefGoogle ScholarPubMed
Kristensen, D, Bauer, J, Hageman, I and Jorgensen, MB (2011) Electroconvulsive therapy for treating schizophrenia: A chart review of patients from two catchment areas. European Archives of Psychiatry and Clinical Neuroscience 261(6), 425–432.CrossRefGoogle ScholarPubMed
Lally, J, Ajnakina, O, Di Forti, M, Trotta, A, Demjaha, A, Kolliakou, A, Mondelli, V, Reis Marques, T, Pariante, C, Dazzan, P, Shergil, SS, Howes, OD, David, AS, Maccabe, JH, Gaughran, F and Murray, RM (2016a) Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine 46(15), 3231–3240.CrossRefGoogle ScholarPubMed
Lally, J and Gaughran, F (2019) Treatment resistant schizophrenia - review and a call to action. Irish Journal of Psychological Medicine 36(4), 279–291.CrossRefGoogle Scholar
Lally, J and Maccabe, JH (2015) Antipsychotic medication in schizophrenia: A review. British Medical Bulletin 114(1), 169–179.CrossRefGoogle ScholarPubMed
Lally, J, Tully, J, Robertson, D, Stubbs, B, Gaughran, F and Maccabe, JH (2016b) Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. Schizophrenia Research 171(1–3), 215–24.CrossRefGoogle ScholarPubMed
Lin, HT, Liu, SK, Hsieh, MH, Chien, YL, Chen, IM, Liao, SC, Tsai, HJ and Wu, CS (2017) Impacts of electroconvulsive therapy on 1-year outcomes in patients with schizophrenia: A controlled, population-based mirror-image study. Schizophrenia Bulletin. sbx136-sbx.Google Scholar
Meltzer, HY (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin 18(3), 515–42.CrossRefGoogle ScholarPubMed
Meltzer, HY (1997) Treatment-resistant schizophrenia–the role of clozapine. Current Medical Research and Opinion 14(1), 1–20.CrossRefGoogle ScholarPubMed
Petrides, G, Malur, C, Braga, RJ, Bailine, SH, Schooler, NR, Malhotra, AK, Kane, JM, Sanghani, S, Goldberg, TE, John, M and Mendelowitz, A (2015) Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry 172(1), 52–8.CrossRefGoogle ScholarPubMed
Sinclair, DJM, Zhao, S, Qi, F, Nyakyoma, K, Kwong, JSW and Adams, CE (2019) Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database of Systematic Reviews (3), CD011847.Google ScholarPubMed
Sommer, IE, Begemann, MJ, Temmerman, A and Leucht, S (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: A quantitative literature review. Schizophrenia Bulletin 38(5), 1003–11.CrossRefGoogle ScholarPubMed
Stewart, R, Soremekun, M, Perera, G, Broadbent, M, Callard, F, Denis, M, Hotopf, M, Thornicroft, G and Lovestone, S (2009) The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: Development and descriptive data. BMC Psychiatry 9(51), 9–51.CrossRefGoogle ScholarPubMed
Taylor, DM (2017) Clozapine for treatment-resistant schizophrenia: Still the gold standard? CNS Drugs 31(3), 177–80.CrossRefGoogle ScholarPubMed
Tharyan, P and Adams, CE (2005) Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews (2), CD000076.Google Scholar
Ward, HB, Szabo, ST and Rakesh, G (2018) Maintenance ECT in schizophrenia: A systematic review. Psychiatry Research. 10.1016/j.psychres.2018.03.033.CrossRefGoogle ScholarPubMed
Youn, T, Jeong, SH, Kim, YS and Chung, IW (2019) Long-term clinical efficacy of maintenance electroconvulsive therapy in patients with treatment-resistant schizophrenia on clozapine. Psychiatry Research 273, 759–66.CrossRefGoogle ScholarPubMed
Zheng, W, Cao, XL, Ungvari, GS, Xiang, YQ, Guo, T, Liu, ZR, Wang, YY, Forester, BP, Seiner, SJ and Xiang, YT (2016) Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: Meta-analysis of randomised controlled trials. PLoS One 11(6), e0156510.CrossRefGoogle Scholar